#USA #Veeva Systems #Amgen #Pleasanton #Vault CRM

Amgen and Veeva Vault CRM Partnership: A New Era in Biotech

In a significant move for the biotechnology sector, Amgen, a major player in the global market, has officially announced its intention to adopt Veeva Vault CRM across its worldwide operations. This strategic decision is underpinned by a decade-long collaboration between Amgen and Veeva Systems, emphasizing their commitment to innovation and patient care.

Scott Skellenger, Senior Vice President and Head of IT at Amgen, highlighted the transformative potential of this transition. He stated, “The shift to Vault CRM will expedite our efforts to provide new therapies to patients around the world with greater speed and flexibility.” This sentiment reflects Amgen’s ongoing commitment to enhancing accessibility to life-saving medications, particularly in the face of increasingly complex healthcare challenges.

The Role of Vault CRM

Veeva’s Vault CRM is not just a software tool; it is the foundation for agent-assisted commercial processes that fundamentally alters how the biotech industry interacts with healthcare professionals (HCPs). This change aims to accelerate time-to-market for new therapies while simultaneously improving patient outcomes. Among its innovative features is the Agentic Call Report™, which generates Commercial Evidence™, revealing hidden barriers to treatment that can stifle patient access.

Matt Farrell, President of Business Strategy at Veeva, expressed enthusiasm for the partnership, stating, “Vault CRM will create the agent-assisted foundation for commercial processes that enable Amgen to provide millions of patients with innovative medicines to combat some of the world’s most severe diseases.” This collaboration marks a pivotal moment as it fortifies the infrastructure necessary for Amgen to roll out essential new therapies on a global scale.

Veeva Systems: A Trusted Partner in Life Sciences

Veeva Systems stands at the forefront of industry-specific solutions tailored for the life sciences sector. With a commitment to innovation, product quality, and customer success, it serves over 1,500 clients, ranging from the largest pharmaceutical companies to emerging biotech firms. Veeva's status as a Public Benefit Corporation underscores its dedication to balancing stakeholder interests, ensuring alignment among customers, employees, and shareholders alike.

The introduction of Vault CRM symbolizes more than just a technological upgrade for Amgen; it embodies a crucial step in the broader journey toward reshaping how therapeutic innovations reach patients. By empowering its agents with better tools and a more comprehensive understanding of patient needs, Amgen is poised to enhance its service delivery and establish a stronger foothold in the competitive biotech landscape.

Looking Ahead

As Amgen embarks on this new chapter with Veeva Vault CRM, the company faces a myriad of opportunities and challenges. This bold strategy not only displays a commitment to rapid therapeutic development but also highlights the importance of adaptability in meeting patient needs within a rapidly evolving healthcare environment.

The collaboration between Amgen and Veeva could serve as a blueprint for other companies in the industry, showcasing how leveraging cloud-based solutions can lead to more efficient, responsive healthcare systems that are better equipped to tackle global health challenges. As this partnership unfolds, it will be fascinating to see the ripple effects it will have on the biotech landscape and, ultimately, on patient care worldwide.